Monte Rosa announced that it achieved pre-specified research milestones and earned milestone payments under its strategic collaboration and licensing agreement with Roche. In October 2023, Monte Rosa entered into a strategic collaboration and licensing agreement with Roche to discover and develop MGDs against targets in cancer and neurological diseases. Under the terms of the agreement, Monte Rosa received an upfront payment of $50 million and is eligible to receive future preclinical, clinical, commercial, and sales milestone payments that could exceed $2 billion, as well as tiered royalties
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
- These 2 ‘Strong Buy’ Penny Stocks Could Jump at Least 300%, Says Piper Sandler
- Monte Rosa Therapeutics Reports Progress on Drug Development
- Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160